Exponent, Inc. (NASDAQ: EXPO) — The Compounder, Finally on Sale for the First Time in a Decade

Target: Exponent, Inc. (NASDAQ: EXPO) Sector: Industrials — Research & Consulting Services (science & engineering consulting: failure analysis, litigation/regulatory support, product development; Environmental & Health) Date: 2026-06-04 · Price at writing: ~$59.48 · Shares (basic): ~48.5M · Market cap: ~$2.89B · Net cash: ~$222M (no funded debt) · EV: ~$2.66B Leadership (as of today): CEO Dr. Catherine Ford Corrigan · President Dr. John D. Pye (eff. May 1, 2026) · CFO Eric Anderson (eff. May 1, 2026; Richard Schlenker remains EVP) · Chairman Karen Richardson (eff. today’s June 4, 2026 annual meeting, succeeding the retiring Paul R. Johnston)

Every material claim traces to a primary source. Figures reconcile to the FY2025 Form 10-K (filed 2026-02-27, fiscal year ended 2026-01-02) and the Q1 2026 Form 10-Q (filed 2026-05-08) unless noted. Third-party market data is flagged as unofficial.

⚡ Claude’s Take

This block is the author’s own subjective opinion. It is the single place in this document where a position is taken; it is general information and not investment advice. Everything below it (the numbered sections) is analysis that carries no recommendation and no price target — valuation there is discussed only as embedded expectations and scenarios.

Verdict: BUY / accumulate-on-weakness — a genuine, moaty quality compounder de-rated to its cheapest multiple versus its own history in roughly a decade, with the cyclical wind shifting back to its back. Conviction: medium-high on the business, medium on the entry (it is fair, not cheap). Not a short under any scenario.

Directional zone: I’d accumulate around and below ~$60, lean in harder toward the low-$50s (the 52-week low ~$52, the bear-case floor, and where the ~5.5% shareholder yield + net cash get hard to argue with), and regard base-case fair value as ~$62–76. The re-rate-plus-reacceleration bull path points to ~$90–110, but that is a two-variable bet (earnings recovery and multiple re-expansion) and I won’t underwrite it as the base case. The key fact: this stock fell from ~$82 to ~$59 almost entirely on multiple, not earnings — normalized EPS actually rose in FY2025. You are being handed a ~28%-ROE, net-cash, pricing-power business at ~22x forward instead of the ~38–45x it traded at for most of the last decade.

Why. This is the mirror image of a commodity name: here the quality is not in question — a 55-year, court- and Daubert-tested reputation as the independent “go-to” for failure analysis is a real intangible-asset moat that shows up as 27% operating margins and pricing power (in FY2025 both segments grew revenue on higher billing rates even as billable hours fell). The de-rating was a self-inflicted utilization cycle (over-hired in 2022–23 → right-sized in 2024 → re-accelerating now), compounded by soft big-tech/auto R&D budgets in the small proactive book — not moat erosion. The filings already date the inflection: Q3 2025 revenue +10%, then Q1 2026 revenue +10% / NI +11% / utilization at a cycle-high 76%. The framing is buying the de-rated darling as the cycle turns — quality-compounder-at-a-price, with a capital-return floor under it. My hesitation is honest: ~22x forward is fair, not a bargain, and at that multiple you are paying for the recovery to be real.

What flips me. Bullish trigger: utilization sustaining the mid-to-high-70s with FTE growth — i.e., growth from volume + rate, not rate alone — which confirms the historical algorithm and supports re-rating. Bearish trigger: utilization stalls back at the ~73% ceiling and growth reverts to rate-only/flat hours, confirming the structural-capacity bear and a further de-rate toward the high-teens where slower consulting peers trade. Tag: “The compounder, finally on sale — for the first time in a decade.”

1. Executive Summary

Exponent is a ~$2.9B, asset-light science & engineering consulting firm — roughly 950–1,000 consultants across 90+ technical disciplines (the majority hold doctorates) who are retained to figure out why things fail, who is at fault, and whether a product is safe. It is, on the numbers, one of the highest-quality businesses in the public market: ~22–23% operating margins on net revenue, ~28% return on equity, free-cash-flow conversion of 110–126% of net income, zero funded debt, ~$222M net cash, and a 13-year rising-dividend streak. These returns are not a commodity windfall; they are the financial signature of a durable competitive advantage.

That advantage is, in Greenwald’s taxonomy, an intangible asset: a 55-year, court- and regulator-tested reputation for credible, independent technical analysis. When a company faces a product-liability suit, a recall, a catastrophic failure, or a regulator, it does not hire the cheapest engineer — it hires the firm whose experts survive Daubert challenges and whose name carries weight with judges, juries, insurers, and agencies. That credibility is reinforced by a multidisciplinary scale advantage (90+ disciplines under one conflict-clean roof, which no boutique or in-house team can match for complex cross-disciplinary failures) and by selection/track-record costs in litigation. The moat shows up exactly where Greenwald says it should: in pricing power — in FY2025 both reporting segments grew revenue on higher billing rates even as billable hours fell. Demand is credibility-based and price-inelastic. The company’s own 10-K candidly says “barriers to entry are low” and “competition is increasing”; that is true at the single-discipline level and false at the level of the integrated, court-credible, conflict-clean brand — which is where the moat lives.

The reason this note is timely is a de-rating: the stock fell ~27% from a 52-week high of ~$82 to ~$59, compressing the forward P/E from EXPO’s historical ~38–45x toward ~22x — its cheapest relative to its own history in roughly a decade. Critically, the drop is almost entirely multiple, not earnings. Reported FY2025 net income did dip (-2.7% to $106.0M), but pre-tax income was flat ($147.3M vs $147.4M) and normalized net income actually rose to ~$111M — the reported decline is a tax-line stock-comp swing plus biennial/one-time cost timing. The real story behind the de-rating is a self-inflicted utilization cycle: EXPO over-hired in 2022–23 (technical FTE +10%, utilization collapsing from 74% to 69%), right-sized headcount −8% in 2024 to restore 73% utilization, and then posted two ~flat revenue quarters in early 2025 that broke its premium-compounder multiple — all compounded by soft big-tech and automotive R&D budgets in its smaller “proactive” book. The filings then date a clean inflection: Q3 2025 revenue +10%, Q1 2026 revenue +10% / NI +11% / utilization at a cycle-high 76%.

Capital allocation is a strength: a disciplined “return the excess” policy (no debt, minimal capex, no empire-building M&A), a 13-year dividend-growth streak (~8% CAGR), and an opportunistic $97.8M buyback in FY2025 stepped up 17-fold into the share-price weakness — relative valuation discipline, even if ~$72/share was still ~35x. The honest blemishes are minor: CEO incentive metrics (a +3% revenue-growth bar and a margin target) are undemanding and lack a per-share/return-on-capital linkage; insiders show no conviction open-market buying (only routine 10b5-1 sales); and there is a known out-year cost step (Arizona land-lease rent rising ~$5.2M/year from January 2028).

On valuation, the debate is entirely about price and the cyclical-vs-structural growth question, not quality. At ~22x forward / ~22x EV/EBITDA / ~5x net revenue, EXPO is the most expensive and the highest-quality name in its comp set — a ~70% EV/EBITDA premium to its closest pure peer, CRA International. Reverse-engineered, ~$59 prices ~4–7% long-run FCF growth at a normal 8–9% discount rate (below EXPO’s historical algorithm) or ~8–9% at a demanding 10% rate. This note takes no position and sets no price target in the numbered analysis; it frames the embedded expectations and scenarios below. The one-line synthesis: a great business, de-rated from expensive to reasonable, contingent on the visible Q3’25/Q1’26 recovery proving durable rather than a cyclical head-fake.

2. Business Overview

2.1 What the company actually does

Exponent is a multidisciplinary engineering and scientific consulting firm. Its consultants — engineers, scientists, physicians, regulatory and environmental specialists — are hired to investigate accidents and failures, support litigation as expert witnesses, evaluate the safety and reliability of products before and after launch, and navigate regulatory requirements. The work is split two ways that matter more than the formal segments:

• Reactive work — failure analysis, accident reconstruction, product-recall investigations, and litigation/dispute support. This is the high-margin core, it is counter-cyclical and largely non-discretionary (failures, lawsuits, and recalls happen regardless of the economy — sometimes more in downturns), and it is where the brand/credibility moat is most valuable.
• Proactive work — product-development engineering support, reliability testing, regulatory and environmental/health consulting. This tracks client R&D and capital budgets and is therefore more cyclical and more competitive.

The company does not disclose an exact reactive/proactive split (a Street estimate is ~50/50; unconfirmed — an open question), but the distinction is the key to understanding both the moat and the recent cyclicality.

2.1a Origins — why the history matters

Exponent traces to Failure Analysis Associates, founded in 1967 by Stanford engineering professors to investigate why structures, vehicles, and products fail. That heritage is not trivia: the firm’s identity and credibility were built over nearly six decades of high-stakes forensic work — investigating crashes, fires, explosions, structural collapses, and product defects — long before “litigation consulting” was an industry. The rebrand to Exponent and the gradual broadening from pure failure analysis into litigation support, product-safety/reliability, regulatory, and environmental/health sciences layered higher-growth adjacencies onto a forensic core whose reputation was already established. The practical consequence for an investor: the moat (Section 4) is the cumulative product of ~60 years of Daubert-surviving testimony and defensible analyses — it cannot be bought or built quickly, which is precisely why it is durable and why the firm earns ~28% returns in a nominally “low-barrier” industry.

2.2 Reporting segments

EXPO reports two segments:

• Engineering & Other Scientific (~85% of revenue). Mechanical, electrical, materials, civil/structural, biomechanics, polymer science, electronics, vehicle engineering, human factors, data sciences, and more. FY2025 segment revenue ~$493.9M (+5.2%), operating income ~$173.6M (+5.3%), utilization ~74%. This is the healthy engine.
• Environmental & Health (~15% of revenue). Chemical regulation/EHS, toxicology, epidemiology, environmental and health sciences. FY2025 revenue ~$88.1M (−1.0%), operating income ~$30.6M (+1.9%), utilization ~66%. This smaller segment is the source of the recent demand softness — specifically “a lower level of activity for our regulatory services in the chemical industry.”

2.3 How it makes money — the consulting-firm KPIs

EXPO’s economics are driven by a handful of operating metrics that matter more than the GAAP lines:

• Net revenues (revenues before reimbursements) — the primary top line (~92% of gross revenue; reimbursements are zero-margin pass-throughs). FY2025 net revenue was $536.8M.
• Utilization — the percentage of available consultant hours that are billable. This is the single most important profitability driver (see Section 6).
• Technical full-time-equivalent (FTE) headcount and billable hours — the capacity.
• Billing rates / revenue per FTE — the pricing.

Because the firm sells expert hours, its only “inventory” is the time of credentialed people, and its margin is set by how fully and at what rate that time is billed. This is the asset-light, talent-driven model that produces both the high returns and the capacity constraint.

2.4 Customers, end markets, and recurrence

Clients are corporations, law firms, insurers, and government agencies. End-market exposure in FY2025 was diversified — consumer products ~21%, energy/utilities ~20%, transportation ~16%, chemical ~11%, plus life sciences, construction, and others — with meaningful exposure to big-tech/consumer-electronics and automotive/EV clients whose R&D budgets drove the recent proactive softness, partly offset by utilities and chemical-regulatory demand. Revenue is project-based, not contractually recurring, but a different and arguably more durable kind of recurrence operates: a continuous flow of failures, disputes, recalls, and regulatory events that, in aggregate, is steadier than most cyclical industrials — and a roster of repeat corporate and law-firm clients who return because the firm’s prior work product holds up. EXPO carries no funded debt, ~$222M of cash, and finances itself entirely from operations.

3. Industry Dynamics

3.1 A good business in a structurally mediocre industry

The broad science & engineering / expert-witness consulting industry is structurally mediocre: it is highly fragmented (an estimated ~12,000 US expert-witness firms), barriers to entry at the individual-discipline level are genuinely low (a single credentialed expert can hang out a shingle), and category growth — perhaps ~6% historically — decelerated toward ~1% in 2025. EXPO’s own 10-K concedes this: “barriers to entry are low… competition is increasing,” and clients increasingly raise “independence concerns.” Taken at face value, that is an unattractive industry.

The resolution of the apparent paradox — a mediocre industry housing a 28%-ROE business — is that EXPO competes in a defensible niche within that industry. Low barriers to enter any one discipline coexist with high barriers to replicate EXPO’s specific platform: a 55-year, Daubert-tested brand; ~950–1,000 consultants across 90+ disciplines under one conflict-clean roof; and the independence that lets it serve as a credible third party precisely because it is not the client’s in-house team. That is an intangible-asset-plus-scale moat operating inside a niche, and EXPO’s durable premium margins validate it. The honest framing: a good business in a mediocre industry.

3.2 The value chain and the competitive set

EXPO’s competitors are heterogeneous and, tellingly, none replicates its full bundle:

• Other technical/forensic consultancies — Engineering Systems Inc. (ESI), S-E-A, Rimkus, Robson Forensic — mostly smaller, regional, or narrower in disciplinary scope.
• Litigation-economics firms — CRA International (CRAI, the closest public comp), FTI Consulting, Cornerstone — but these skew toward economic/financial expert work rather than hard-science/engineering failure analysis.
• In-house corporate engineering teams — which lack the independence courts and regulators require.
• Individual academic expert witnesses — credible but un-scaled, without the multidisciplinary bench or institutional reliability.
• Large E&C/EHS firms — ERM, Ramboll, Arcadis, WSP — competitors on the environmental side but not in litigation-grade failure analysis.

EXPO sits as the premium, independent, niche leader in court-credible multidisciplinary failure analysis. The barrier is not any single discipline; it is the integrated, conflict-clean, brand-name bundle.

3.3 Demand drivers and cyclicality

Overall cyclicality is low-to-moderate, a function of the reactive/proactive mix:

• Reactive demand is counter-cyclical and non-discretionary. Product failures, recalls, mass torts, and insurance disputes are driven by litigation volume, recall frequency, product complexity, and regulatory enforcement — not GDP. US recalls have run at multi-year highs (CPSC recalls rose ~40% from 238 in 2020 to 333 in 2024, with 2025 setting records), a structural tailwind for the reactive core.
• Proactive demand is pro-cyclical, tied to client R&D and capital budgets — the current soft spot, concentrated in throttled big-tech/consumer-electronics and automotive/EV R&D spending, and in chemical-regulatory activity within the Environmental & Health segment.

The net business is therefore far less cyclical than most industrials, but not acyclical — the recent slowdown is precisely the pro-cyclical proactive book and end-market budget cuts, not the reactive moat.

3.4 Secular tailwinds and the AI question

Tailwinds: rising product complexity (EV batteries and thermal-runaway events, AI/data-center hardware, autonomous systems, medical devices), increasing litigation and regulatory intensity, PFAS/CERCLA and chemical-regulation pipelines, and a high insurance-claims environment. Regulation is a structural support, not a threat: under Daubert and Federal Rule of Evidence 702 (amended December 1, 2023 to tighten admissibility), expert testimony legally requires a credentialed, defensible human expert — a legal moat around EXPO’s core that no software can fill. On the AI question specifically, the prevailing 2025–26 legal consensus is that AI augments rather than replaces expert testimony (admissible testimony requires human attestation and cross-examination), and AI is itself creating new demand categories — AI-product-liability, algorithmic-harm, and AI-detection experts. The assessment here is that AI is net-augmenting to the reactive core, not displacing it.

3.4a The specific secular demand vectors

The “rising product complexity” tailwind is concrete, not abstract, and each vector maps to a discipline EXPO already staffs:

• EV batteries and energy storage. Thermal-runaway events, battery fires, and the safety/reliability questions around lithium-ion systems are a high-growth failure-analysis category — simultaneously a materials, electrochemical, thermal, and electrical problem, exactly the cross-disciplinary work that favors EXPO’s integrated bench over a boutique. The paradox of the current cycle is that the same automotive/EV clients cutting proactive R&D budgets generate reactive failure and litigation work when products fail in the field.
• AI and data-center hardware. GPU-dense data centers, power and thermal systems, and the reliability of AI hardware are an emerging engineering-failure and product-liability frontier; separately, AI products are spawning a new litigation category (algorithmic harm, autonomous-system failures) that requires credentialed experts.
• Medical devices and life sciences. Device failures, recalls, and product-liability suits draw on EXPO’s biomechanics, materials, and health-sciences disciplines — a steady, regulation-driven demand source.
• PFAS, CERCLA, and chemical regulation. The Environmental & Health segment is levered to a multi-year regulatory pipeline (PFAS “forever chemicals,” TSCA, EU REACH) — currently soft on the chemical-industry proactive side but a structural long-term driver.
• Recall and litigation intensity. The reactive core rides a secular rise in product recalls (CPSC recalls +~40% from 238 in 2020 to 333 in 2024, with 2025 a record) and the tightened Daubert/FRE 702 admissibility bar that raises the premium on credible, defensible experts — a regulatory change that directly favors the incumbent with the best track record.

The investment-relevant point: EXPO’s demand is diversified across vectors that are individually cyclical but collectively steady, and the reactive/proactive split means a downturn in one (client R&D budgets) is partly offset by strength in another (failures, recalls, disputes).

3.5 Verdict — industry & niche

The broad industry is mediocre; EXPO’s niche within it is structurally attractive and defensible. The combination of a legal moat (Daubert-required human experts), a counter-cyclical non-discretionary reactive core, secular complexity/regulation tailwinds, and an AI dynamic that augments rather than displaces makes EXPO’s specific position far better than the fragmented “consulting” label suggests. The live risk is end-market cyclicality (the tech/auto R&D pullback in the proactive book), not moat erosion.

4. Competitive Position

4.1 Naming the moat (Greenwald)

• (a) Intangible asset — the primary moat. EXPO’s 55-year, court- and regulator-tested reputation for credible, independent technical analysis is the core advantage. Clients who could do the engineering in-house retain Exponent specifically for third-party credibility — a quality an internal team structurally cannot supply. This is the textbook Greenwald intangible: a brand that commands a price premium and customer preference that competitors cannot quickly replicate. The barrier is time and track record — decades of Daubert-surviving testimony and high-stakes failure analyses that built the name.
• (b) Economies of scale within a niche — the reinforcing moat. 90+ technical disciplines and 700+ doctorate-holders under one roof let EXPO staff complex, cross-disciplinary failures (a battery fire that is simultaneously a materials, electrical, thermal, and human-factors problem) that a boutique cannot. Crucially, this scale is conflict-clean and independent — a single firm that can field the whole team without the client’s fingerprints on the analysis.
• © Selection / track-record costs. In litigation, you hire the firm whose experts win — a track record compounds, and switching to an unproven expert carries real case risk. This is a softer, per-engagement switching cost, but it reinforces repeat retention.

There is no classic demand-captivity (no contractual lock-in or habitual repurchase in the consumer sense) — but credibility-based selection in high-stakes matters functions similarly.

4.2 Where the moat shows up in the numbers

A moat that cannot be tied to a financial outcome is not a moat. EXPO’s passes the test cleanly:

• Pricing power. The single clearest fingerprint: in FY2025 both segments grew revenue on higher billing rates even as billable hours fell ~2%. Raising price into softening volume is the behavior of inelastic, credibility-based demand — clients pay up because the name on the report matters. Net revenue per FTE rose ~16% over two years to ~$552k.
• Margins. ~22–23% operating margin on net revenue and ~27% on a gross basis — multiples of the ~10–13% margins at peer consultancies (CRAI, FTI, Huron).
• Returns. ~28% ROE and an effectively infinite ROIC (net cash, asset-light, minimal capital required to grow).

If you removed “the Exponent name,” billing rates, utilization, and returns would all collapse — the moat is real and durable.

4.3 The honest counter-evidence, reconciled

The bear must contend with EXPO’s own disclosure that “barriers to entry are low” and “competition is increasing,” and with rising client “independence concerns.” These are real and correctly reconciled: the barriers are low to enter any one discipline and high to replicate the integrated, court-credible, conflict-clean, brand-name platform. The moat sits at the firm/reputation level, not the individual-engineer level. The genuine vulnerability is not competitive entry but talent: the moat is the PhD bench, and the model is talent-capacity-constrained — utilization has historically topped out around the low-to-mid 70s%, which caps how fast EXPO can grow without diluting quality.

4.3a The talent engine — the moat’s power source

Because the moat is the assembled bench of credentialed experts, the mechanism that recruits, retains, and motivates that bench is itself part of the competitive advantage and deserves explicit attention. EXPO’s profit-sharing bonus pool (33% of pre-bonus pre-tax profit) does triple duty: it aligns the workforce with firm profitability, it stabilizes margins (the accrual flexes down when utilization falls — Section 6.4), and it is a powerful retention tool that ties elite PhDs’ compensation to the collective enterprise rather than to portable individual books of business. This matters because the classic failure mode of a people-based professional-services firm is that the talent is the asset and can walk out the door — taking client relationships with it. EXPO mitigates this structurally: the value proposition to a client is the Exponent platform and brand (independence, multidisciplinary scope, court-tested name), not a single star expert, so individual departures are less damaging than at a boutique built around one or two marquee names. The flip side, and the genuine risk (Section 4.4), is that the model is capacity-constrained — growth requires continuously recruiting scarce elite talent and billing it at high utilization, which caps the achievable growth rate regardless of demand.

4.3b Direct contrast — EXPO vs. CRA International

CRA International (CRAI) is the closest public comparable and a useful mirror. Both are high-end, credential-driven expert-consulting firms with ~26–28% ROE and similar recent revenue growth (~10.5%). But the businesses differ in ways that justify a quality premium for EXPO: CRA skews toward economic and financial expert work (antitrust, finance, regulatory economics), which is more competitive (it overlaps with FTI, Cornerstone, and the economics arms of the large advisory firms) and more dependent on individual star economists. EXPO’s hard-science/engineering forensic niche is narrower, more defensible, and less substitutable — you cannot replace a court-credible battery-failure analysis with a generalist. EXPO carries net cash where CRA carries modest net debt; EXPO’s operating margins (~27%) roughly double CRA’s (~13%); and EXPO’s brand independence is harder to replicate. That EXPO trades at a ~70% EV/EBITDA premium to CRA (Section 10) is directionally justified by these quality differences — the valuation debate (Section 10.2) is about the size of the warranted premium, not its existence.

4.4 Verdict — competitive position

A durable competitive advantage — intangible-asset (court-tested brand) plus multidisciplinary scale, validated by pricing power and ~28% ROE. This is a genuinely high-quality competitive position, the opposite of a commoditized service. The durability risks are (1) key-person/talent dependency and the utilization ceiling, and (2) maintaining independence and reputation — a single high-profile compromised engagement could dent the brand. Neither is currently in evidence; both warrant monitoring. EXPO is a higher-quality business than its public consulting peers (CRAI, FTI, Huron, ICF) on margins, returns, and balance sheet, and it is the clear niche leader in court-credible failure analysis.

5. Growth History and Forward Opportunities

5.1 Historical growth — steady, organic, talent-gated

EXPO’s growth is organic (essentially no M&A; goodwill is a flat $8.6M) and historically a high-single-digit net-revenue compounder, driven by FTE growth × utilization × billing-rate increases. Net revenues moved $497.2M (FY2023) → $518.5M (FY2024) → $536.8M (FY2025). The headline growth rates (+4.3%, +3.5%) understate the underlying trend because of a fiscal-calendar quirk: FY2024 was a 53-week year. Adjusting FY2024 to a 52-week-equivalent base implies organic FY2024 net-revenue growth of only ~2.3% — which makes FY2025’s +3.5% an acceleration on a like-for-like basis, not a deceleration. This is material to the “slowdown” narrative and is frequently missed.

The real driver of the choppy 2023–2025 optics was a utilization cycle of management’s own making: technical FTE rose +10% in 2023 while billable hours grew only +2%, collapsing utilization from 74% to 69% (too many bodies, not enough billable demand); FTE was then cut −8% in 2024 to restore utilization to 73%; and FY2025 held FTE roughly flat with utilization at 73% while net revenue grew entirely on rate. This was a normalization cycle, not a structural decline.

5.2 Forward opportunities

• Cyclical recovery (the near-term lever). The filings date a clear inflection: Q3 2025 net revenue +10% YoY with FTE turning positive (+3%), confirmed by Q1 2026 (+10% revenue, +11% NI, FTE +5% to 1,013, utilization at a cycle-high 76%), with FY2026 guided to high-single-digit growth. Notably, Q1 2026’s strength was led by a proactive (consumer-electronics) recovery — the very book that had been soft.
• Reactive secular tailwind. Record product-recall volumes, rising litigation/Daubert demand, EV/battery failure analysis, and a PFAS/EHS regulatory pipeline feed the counter-cyclical core.
• Pricing power. Demonstrated ability to push billing rates (implied ~+5–6% on Engineering in FY2025) provides a growth lever independent of headcount.
• Operating leverage on utilization. If utilization grinds from 73% toward the high-70s on a roughly fixed cost base, incremental margins are high — the bull-case earnings lever.

5.3 The constraint, and the verdict

The binding limit is talent capacity. EXPO grows by recruiting and retaining elite PhDs and billing them at high utilization; utilization has historically ceiled in the low-to-mid 70s%. Whether 76% (Q1’26) can be sustained and extended is the single biggest unmodeled unknown — it separates a return to the historical ~8–10% algorithm (bull/base) from a rate-only, mid-single-digit grower (bear).

Verdict: high-quality, organic, but talent-gated growth. The growth is real, capital-light, and high-return — but structurally capped by utilization and dependent on continued elite-talent recruitment. The FY2023–25 wobble was cyclical and partly self-inflicted, and the data shows it reversing; the open question is the durability of the reacceleration, not its existence.

6. Financial Quality

6.1 Income statement (GAAP, $000)

Fiscal years end the Friday nearest December 31 (FY2024 = 53 weeks; FY2023/FY2025 = 52 weeks).

6.2 The FY2025 “earnings decline” is a reporting artifact (the centerpiece)

The headline that spooked the market — net income down 2.7% to $106.0M despite revenue up — dissolves on inspection. Pre-tax income was essentially flat ($147,297k vs $147,370k, −$73k). The entire reported NI decline lives below the operating line and in the tax line:

1. Stock-comp excess-tax-benefit swing (the biggest item, ~$3.0M after-tax). FY2024 carried a +$2,793k tax benefit from stock awards; FY2025 a −$254k tax cost. This alone more than explains the $2,993k NI decline and lifted the effective rate from 26.0% to 28.0% — “excluding the excess tax benefit, the effective tax rate would have been 27.9% for both years.” This is non-cash, non-operating noise from RSU grant-versus-vest price timing.
2. Arizona land-lease occupancy (+$1,552k) from a June 2024 15-year lease extension (straight-lined ROU cost; cash impact is back-loaded to 2028 — Section 6.6).
3. Biennial managers’-meeting G&A (+$2,627k) — a company-wide meeting held in Q3 2025 with none in 2024 (it recurs roughly every two years; next in 2027).
4. Lower interest income (−$694k) and lower rental income (−$1,856k) (loss of a Silicon Valley tenant).

Core earnings actually rose: total segment operating income +4.8% ($194.9M → $204.2M), EBITDAS +0.9%, and normalized net income ~$111M (stripping the ~$3.0M tax-swing and the ~$1.9M after-tax biennial meeting) — above FY2024’s $109M. The FY2025 dip is timing and tax-line noise, not margin-structure deterioration.

6.3 The operating-KPI bridge (the heart of the business)

The narrative is entirely visible here: over-hiring in 2022–23 (FTE +10%, utilization to 69%) → right-sizing in 2024 (FTE −8%, utilization restored to 73%) → a rate-driven 2025 plateau (FTE flat, hours −2%, net revenue +3.5% on higher rates) → a Q1 2026 inflection (utilization 76% cycle-high, hours +6%, FTE +5%, with both volume and rate contributing). Net revenue per FTE rose +16% over two years — the clearest evidence the firm captures more value per consultant over time.

6.4 Margins, the bonus-pool stabilizer, and returns

Operating margin on net revenue was a steady 22.4% / 23.1% / 22.3% (FY23/24/25); the ~80bp FY2025 dip is fully attributable to the one-time items above, not pricing or comp leverage. A structural reason EXPO’s margins are unusually stable for a people business is the bonus pool = 33% of pre-bonus pre-tax profit (adjusted): the largest discretionary slug of compensation flexes with profitability, so when utilization or demand falls, the bonus accrual falls and cushions the margin. Total compensation ran a remarkably steady 64.4% / 63.7% / 63.7% of net revenue.

ROE was ~26–27% (NI $106.0M on ~$406M average equity). Two honest caveats: (1) equity is shrinking ($421M → $390M) because buybacks + dividends exceed net income, which mechanically lifts ROE — a capital-return artifact, not pure operating improvement; (2) conventional ROIC is not meaningful because EXPO is net-cash with no funded debt — invested capital is near-zero/negative, so returns on incremental capital are effectively infinite. The cleaner read is that this is a genuinely high-return, minimal-capital-intensity profile (capex 1.6–3.0% of net revenue).

6.5 Cash flow and earnings quality

FCF exceeds net income every year (110–126%), as SBC and D&A add-backs outrun low capex. The FY2025 CFO dip ($144.5M → $131.7M) was a working-capital build — accounts receivable rose $161.4M → $181.5M as billings/rates grew (DSO ~114 days, normal for litigation/consulting WIP) — not an earnings-quality red flag; it is receivables funding higher revenue. Earnings quality is otherwise high: no acquisitions/goodwill churn, no impairments, KPMG as auditor since 1987 with a clean opinion and a single critical audit matter (AR collectability), and conservative accounting (RSUs expensed, leases on balance sheet, services billed as performed). Two recurring sources of non-operating noise to normalize: rate-sensitive interest income ($7–10M/year on the cash pile) and the deferred-comp/rabbi-trust mark-to-market (gains/losses run through both other income and comp expense and largely net at the NI line). For run-rate, use the ~28% normalized tax rate, not the swinging GAAP rate.

6.6 Balance sheet

The balance sheet is pristine: ~$221.9M cash and equivalents, zero funded debt (the ~$83M “debt” in screening tools is the operating-lease liability), plus a $123.5M rabbi-trust investment portfolio economically offset by the deferred-comp liability. There is no revolver drawn and no notes outstanding. The one forward item to flag is the Arizona land-lease step-up: rent of ~$1.0M/year jumps to ~$6.2M/year for the 15-year extension starting January 17, 2028 — a future ~$5.2M/year cash drag (~$0.07–0.08/share after tax), already partly carried in the P&L via straight-lined ROU expense but a real out-year headwind to model.

6.7 Verdict — financial quality

Genuinely high-return and high-quality. ~22–23% net-revenue operating margins, ~28% ROE, FCF > NI, zero funded debt, ~$222M net cash, minimal capex, a built-in bonus-pool margin stabilizer, and demonstrated pricing power. The FY2025 dip is one-time/cyclical, not structural — core operating earnings rose, and Q1 2026 confirms the inflection. The only genuine demand softness is the small (~15%) Environmental & Health segment. This is among the cleanest financial profiles in the public market; the question the rest of the note addresses is not whether it is high-quality but what it is worth.

7. Capital Allocation

7.1 The policy and the scorecard

EXPO runs a textbook “return the excess cash” policy for a high-ROIC, asset-light compounder: no funded debt, minimal capex, no empire-building M&A, and the rest returned via a steadily growing dividend plus buybacks. The scorecard:

• Dividend: $1.04 → $1.12 → $1.20/share (FY23/24/25), ~8% CAGR, 13 consecutive years of payment/increases since 2013, ~55–57% payout (well-covered, since FCF > NI), ~2.1% yield. The quarterly dividend stepped $0.26 → $0.31 over the window.
• Buybacks: $24.2M (FY23) → $5.7M (FY24) → $97.8M (FY25, ~1.35M shares at ~$72 avg) — a 17-fold step-up, with a fresh $100M authorization reloaded October 2025 (~$96.5M remaining) and an additional $50M added April 2026.
• Total FY2025 capital returned: ~$158.6M (~$97.1M buyback + $61.5M dividends), exceeding both FCF (~$122M) and net income ($106M) — funded from the cash pile (cash fell $258.9M → $221.9M), which is why equity shrank.
• Total shareholder yield ~5.5% (2.1% dividend + ~3.4% buyback).
• Net share count finally fell (diluted weighted 51,635k → 51,244k) as the large FY2025 buyback outpaced SBC dilution.

7.2 Buyback discipline — the key test

EXPO has historically traded at a premium multiple, so the relevant question is valuation-aware repurchasing. The record passes, on a relative basis: management bought little at peak multiples (FY2023–24, when the stock was richest) and stepped up 17-fold into the ~28% drawdown — counter-cyclical to its own share price, and value-additive relative to its history. The honest caveat: ~$72/share was still ~35x earnings against falling billable hours, so this is relative discipline, not absolute bargain-hunting. Still, for a company that could easily have bought back stock mechanically at the highs, the demonstrated willingness to lean in on weakness is a genuine positive.

7.3 Reinvestment vs. return

EXPO reinvests through hiring and office space, not acquisitions — appropriate for an organic, talent-gated compounder where the binding constraint is recruitable elite talent, not capital. Given ~28% ROE and a utilization ceiling, “grow organically at high returns and return the rest” is the correct policy; retaining more capital would not accelerate growth (the constraint is people, not money) and would dilute returns. The one critique is philosophical: with a fortress balance sheet and a high-conviction moat, a larger opportunistic buyback at the current de-rated multiple (rather than spreading returns across a steady dividend) would arguably compound per-share value faster — and management’s FY2025 step-up suggests it agrees.

7.4 Compensation & incentives

From the 2026 proxy: the firm-wide bonus pool = 33% of pre-bonus pre-tax profit ($77.2M in FY2025), covering all NEOs, with 40% of NEO bonus deferred into 4-year RSUs — a structure that ties pay to profitability and retention. CEO total compensation is modest at ~$3.74M (pay ratio ~19:1) — strikingly low for a ~$2.9B-market-cap firm and a point in management’s favor. Say-on-pay support was 95.7%. The blemish: the CEO performance-award metrics are undemanding and not per-share-linked — a +3.0% revenue-growth target (actual +3.52%) and a 31.71% adjusted-EBITDAS margin — with no ROIC, EPS, or TSR metric. For a business whose entire value proposition is per-share compounding and capital efficiency, the absence of a return-on-capital or per-share linkage is a real (if minor) governance gap.

7.5 Insider behavior

The 36-month Form 4 corpus shows zero discretionary open-market purchases (code P) — only routine option exercises and 10b5-1-planned sales by long-tenured principals and officers (CEO Corrigan’s transactions carry the 10b5-1 flag and the “cover exercise cost + taxes” footnote). There is no conviction buying into the dip by any insider — a missing positive — but equally no red-flag dumping. Aggregate insider ownership is low (~1.7%; Corrigan holds 269,426 shares, <1%); the register is institution-dominated (BlackRock ~12%, Vanguard ~10%). The insider signal is neutral.

7.6 Verdict — capital allocation

A clear strength. Pristine net-cash balance sheet, a 13-year rising dividend, valuation-aware opportunistic buybacks (stepped up into weakness), modest CEO pay, and a profit-pool comp structure that stabilizes margins and aligns the workforce. The qualifications are minor and honest: buyback discipline is relative not absolute; the cash drawdown mechanically flatters ROE; and CEO incentives lack a per-share/return-on-capital metric. None undermines the thesis that management is a disciplined steward of a high-return business.

8. Changes and Headwinds — Last Two Years

8.1 The de-rating timeline

The ~$82 → ~$59 slide was an organic-growth de-rating, not an event-driven collapse. The damaging prints were Q2/Q3 2024 (technical FTE down ~9–10% YoY as the right-sizing showed up as shrinking billable capacity) and the two flat (~0% YoY) revenue quarters of Q1 and Q2 2025, which undercut EXPO’s premium-compounder multiple — for a stock priced at ~40x for secular compounding, two flat quarters are enough to break the narrative. The fundamental inflection is Q3 2025 (revenue +10% YoY to $137.1M, FTE +3%), confirmed by Q1 2026 (+10% revenue, +11% NI, FTE +5%, utilization 76%).

8.2 Management transition (recent, orderly)

An orderly leadership refresh completed in 2026: long-time CFO Rich Schlenker stepped back to EVP, with internal successor Eric Anderson becoming CFO effective May 1, 2026; Dr. John Pye was named President (also May 1); and Chairman Paul Johnston retired from the board at today’s June 4, 2026 annual meeting, with Karen Richardson elevated to Chairman. Dr. Catherine Corrigan continues as CEO. All moves are internal-continuity, not disruption — but a new CFO and a recomposed board are worth monitoring for any change in the capital-return or hiring cadence.

8.3 One-time items to normalize (run-rate hygiene)

For modeling: (1) the 53-week FY2024 flatters FY2024 / understates FY2025 comps (~$10M extra week); (2) the biennial managers’-meeting (~$2.0–2.6M G&A, hits odd years in Q3 — drove Q3’25 G&A +44% YoY; next in 2027); (3) the SBC excess-tax-benefit swing (±~2pts on the effective rate); (4) deferred-comp mark-to-market (NI-neutral, but inflates/deflates revenue-adjacent and cost lines); and (5) the forward Arizona rent step-up (~$5.2M/year from January 2028).

8.4 Recent news check

Recent news flow on the stock has been quiet. The most notable item was a routine 10b5-1 open-market sale by a group VP (2,000 shares at ~$57.47) — plainly a planned diversification sale (consistent with zero code-P buys across the corpus), non-thesis-changing.

8.5 Verdict

The last two years net to a temporarily-stalled-then-reaccelerating compounder that the market re-rated downward on the stall and a new, internally-promoted management team. The changes do not weaken the franchise — the moat, margins, balance sheet, and pricing power are intact — and the operating data shows the cyclical headwind reversing. The thesis-relevant change is the multiple, not the business.

9. Risk Analysis

Highest-conviction risks: #1 (valuation/further de-rate) and #2 (utilization ceiling) — both are price/growth risks, not franchise risks. This is the defining feature of the EXPO setup: the business is safe; the multiple and the growth rate are where the money is made or lost.

10. Valuation Discussion (embedded expectations — no price target)

10.1 The de-rating in context (the crux)

EXPO is a textbook beloved quality-compounder that historically commanded a premium ~35–45x trailing P/E (with decade peaks above 50x). It now trades ~27.8x trailing / ~21.6x forward / ~22x EV/EBITDA / ~5.2x net revenue — roughly 26% below its own median trailing multiple and ~50% below peak. The essential fact: the ~27% price drop is almost entirely multiple compression, not earnings — normalized EPS actually rose FY2024 → FY2025 (~$2.11 → ~$2.16). This is a pure de-rating. The market re-priced the growth/quality premium, not the cash flows.

Is ~22x forward cheap, fair, or expensive for EXPO? Relative to its own history, it is the cheapest in roughly a decade — EXPO has rarely traded below ~30x trailing outside brief panics. In absolute terms, it is not cheap — ~22x forward / ~22x EV/EBITDA / ~5x net revenue is a premium professional-services multiple. The de-rating took EXPO from “very expensive” to “reasonably-priced-for-the-quality,” not to “bargain.”

10.2 Comp table (public market-data aggregators, 2026-06-04; unofficial, reconcile)

Read: EXPO is the most expensive and the highest-quality name in the set. The premium is earned on quality, not growth: it has the highest margins (op ~27% vs peers’ ~10–13%), the only net-cash balance sheet in the table, ~28% ROE, and asset-light high-FCF economics — but its +10.5% revenue growth (a Q1’26-inflection figure) is merely mid-pack (HURN +12%, CRAI +10.5%). The central tension: EXPO trades at a ~70% EV/EBITDA premium to its closest pure comp, CRAI (~13x), for genuinely better economics (higher margins, net cash, court-tested-brand moat, lower cyclicality). A premium is warranted; whether ~70% is the right premium is the debate — a normalization to, say, a 50–60% premium over CRAI would still leave EXPO at ~19–20x EV/EBITDA, i.e., there is room for further relative de-rating even granting EXPO is the best business in the group.

10.3 Embedded-expectations analysis (the centerpiece)

With EV ~$2.66B, normalized FCF ~$122–128M, and normalized EPS ~$2.16, a reverse-DCF (two-stage, 2.5% terminal; EXPO is net-cash so equity FCF ≈ FCFF) implies the long-run growth ~$59 is paying for:

Interpretation: at a normal 8–9% cost of equity for a net-cash, low-cyclicality, ~28%-ROE business, ~$59 requires only ~4–7% long-run growth — below EXPO’s historical ~8–10% algorithm. On that read, the de-rating has marked EXPO down to a mid-single-digit terminal grower, and the stock no longer demands premium-growth heroics. At a demanding 10% rate, ~$59 embeds ~8–9% growth — i.e., the market is still pricing roughly the historical algorithm intact. The “is ~22x cheap?” answer flips on the cost-of-equity assumption — which is why this note flags it rather than asserting one rate as truth.

What the market is pricing correctly vs. incorrectly: Correctly — that EXPO is no longer a 15%+ grower and the 2021–22 reactive/consumer-electronics-boom multiple (40–50x) was unsustainable; the de-rating itself is rational. Potentially incorrectly (the variant) — the market may be extrapolating the 2024–H1’25 trough (two flat quarters) as the new normal, when the filing record dates a clear Q3’25 inflection (FTE +3%, rev +10%) that continued into Q1’26 (rev +10%, NI +11%, utilization 76%, a cycle high). If the proactive (tech/auto R&D) book recovers on top of the durable counter-cyclical reactive core, the embedded mid-single-digit terminal growth is too low — and the multiple is the thing mispriced, not the earnings. The single biggest swing variable is the durability of the Q3’25/Q1’26 reacceleration.

10.4 Scenario analysis (3-year horizon, FY2028E; normalized FY2025 EPS ~$2.16)

• Bear: tech/auto R&D stays soft, utilization can’t break ~73%, growth is rate-only and rate increases decelerate; the market removes the “secular compounder” label and de-rates toward CRAI-like high-teens. You lose on both a lower EPS path and a lower multiple — landing near the 52-week-low area (~$45–48), which coincides with the conservative DCF (~$48).
• Base: the FY2026 high-single-digit guide holds, utilization grinds to the mid-70s, the reactive core stays steady and the proactive book recovers; ~9% EPS CAGR (including buyback) at a still-premium-but-fair ~25x. Notably, the base case roughly clears today’s price with the multiple merely holding — you are not required to underwrite a re-rate to earn a fair return at ~$59; you are required to believe the cyclical recovery is real.
• Bull: a reactive surge (record recalls + Daubert/PFAS demand) plus a big-tech/auto R&D recovery lifts utilization to the high-70s with operating leverage, restoring low-double-digit growth and re-rating EXPO toward its historical 30–35x. The big-upside path — but a two-variable bet (earnings recovery and multiple re-expansion).

10.5 DCF intrinsic-value sketch (a range, not a point)

A two-stage FCF DCF (r = 8.5%, 10-year stage 1, 2.5% terminal, +$222M net cash):

The current ~$59 sits at/just below the base-case intrinsic estimate (~$62). The range is wide because the whole valuation is a bet on the cyclical-vs-structural growth question; discount-rate choice dominates (at r=10% the base IV falls to the low-$50s; at r=8% it rises to the high-$60s) — present the sensitivity, not false precision.

10.6 The capital-return floor and the quality-vs-price synthesis

A ~5.5% total shareholder yield (2.1% dividend + ~3.4% buyback) plus ~$222M net cash and a 13-year dividend streak provide a genuine valuation support: even in a no-growth world, a 5.5% yield on a net-cash, ~28%-ROE business is a defensible return floor, which makes a deep de-rate toward low-teens multiples (where leveraged, slower peers sit) unlikely absent actual moat erosion — of which there is no evidence.

The synthesis: business quality is not the debate — the moat, margins, pricing power, balance sheet, and capital discipline are all confirmed. The entire debate is price. ~22x forward is fair-to-full for the quality — far below EXPO’s own ~38x history but a ~70% EV/EBITDA premium to its closest comp. Does it adequately discount the cyclical/capacity risk? It discounts some (the de-rating from ~40x already happened) but it still requires the cyclical recovery to be real — at ~22x you are not being paid to assume a structural slowdown. The value is in the re-rate optionality (bull) on top of a base case that roughly holds; the risk is a continued de-rate if the bounce plateaus at the utilization ceiling (bear).

11. Variant Perception

Consensus view: EXPO is a high-quality, expensive compounder whose growth has slowed; the market de-rated it from ~40x to ~22x to reflect a permanently lower growth rate and soft tech/auto R&D demand.

The strongest bull case: The de-rating mistook a cyclical, self-inflicted utilization trough (over-hire → right-size) plus a temporary R&D-budget air-pocket for a structural slowdown. The moat is fully intact (FY2025 pricing power proves it), the reactive core is riding record recall/litigation volumes, and the inflection is already in the data (Q3’25 and Q1’26 both +10% revenue, utilization at a cycle-high 76%). As utilization grinds higher with operating leverage and the proactive book recovers, EXPO returns to its ~8–10% algorithm, the market re-rates it back toward 30x, and you earn the earnings growth plus multiple expansion off a decade-low relative valuation — with a ~5.5% shareholder-yield floor and net cash protecting the downside.

The strongest bear case: EXPO is a fair-to-richly-priced, talent-capacity-capped consultancy whose growth is structurally mid-single-digit. Utilization tops out around 73%, so growth depends on billing-rate increases that cannot compound indefinitely; billable hours fell in FY2025. The premium multiple (~70% over CRAI) embeds a “secular compounder” label that the slowing growth no longer earns, and at ~22x forward the market still isn’t pricing a structural slowdown — so there is room to de-rate further toward the high-teens where slower peers trade, even though the business is excellent. You are paying a premium price for mid-single-digit growth and a utilization ceiling.

The 3–5 assumptions that matter most: (1) Is the FY2025 trough cyclical or structural? — the whole thesis. (2) Can utilization sustainably exceed ~73%? — the growth ceiling. (3) Does the proactive (tech/auto R&D) book recover? — the cyclical swing. (4) What cost of equity is appropriate? — it flips “cheap” vs “fair.” (5) Does the market re-rate, or just hold the multiple? — base vs bull.

What would falsify each side: The bull is falsified by utilization stalling back at ~73% with flat billable hours and rate-only growth over the next 2–4 quarters. The bear is falsified by utilization sustaining the mid-to-high-70s with FTE growth (volume + rate), confirming a return to the historical algorithm.

12. Fact vs. Interpretation Table

13. Open Questions

1. Is the Q3’25/Q1’26 reacceleration durable or a cyclical head-fake? — the single most important unresolved question; no public datapoint fully resolves it.
2. Is ~73–76% utilization a hard structural ceiling, or can it grind to the high-70s? — the growth-cap question; Q1’26’s 76% is the most recent and most bullish print.
3. Exact realized billing-rate increase % — undisclosed (implied ~+5–6% on Engineering); determines whether rate-only growth can persist if hours stay flat.
4. The reactive/proactive revenue split — undisclosed (~50/50 is a Street assumption); matters for sizing the counter-cyclical core.
5. Cost of equity — 8% vs 10% flips the embedded-expectations read from “fair” to “cheap”; a judgment call, not a fact.
6. DSO ~114 days — is the FY2025 AR build rate-driven or collection-slowing? (KPMG’s critical audit matter.)
7. New management cadence — will the May/June 2026 CFO/President/Chair transition change the hiring or capital-return posture?
8. AZ rent step-up modeling — confirm the precise FY2028 incremental P&L/cash drag (~$5.2M/yr).

14. What Must Be True

Bull case — what must be true

• The FY2025 trough was cyclical, and the Q3’25/Q1’26 reacceleration is the start of a return to the historical ~8–10% algorithm.
• Utilization sustains the mid-to-high-70s with FTE growth (volume + rate), generating operating leverage.
• The proactive (tech/auto R&D) book recovers on top of a steady, record-volume reactive core.
• The market re-rates EXPO back toward its historical premium as the “secular compounder” narrative is reinstated.
• Falsification test: utilization stalls back at ~73% with flat billable hours and rate-only growth for 2–4 quarters — would break the bull case.

Bear case — what must be true

• Utilization is structurally capped around 73% and growth is rate-only and mid-single-digit — a slower terminal rate than the multiple implies.
• The premium multiple (~70% over CRAI) continues to compress toward the high-teens as the “secular compounder” label is removed.
• Tech/auto R&D softness persists or recurs, keeping the proactive book a drag.
• Falsification test: utilization sustaining the mid-to-high-70s with FTE growth (volume and rate), confirming a return to the historical algorithm — would falsify the structural-ceiling bear.

15. Source Appendix

The full, organized source list — primary SEC filings (FY2023–FY2025 10-Ks, Q1’26 and prior 10-Qs, 2024–2026 proxies, the 36-month 8-K and Form 4 corpus), company disclosures, market data, and secondary industry sources — is maintained in Appendix B below.

Key primary sources: Exponent FY2025 Form 10-K (filed 2026-02-27, FY ended 2026-01-02); FY2024 10-K (filed 2025-02-28); FY2023 10-K (filed 2024-02-23); Q1 2026 Form 10-Q (filed 2026-05-08); 2026 DEF 14A (filed 2026-04-20); April 2026 8-K (leadership transition); SEC Form 4 corpus (CIK 0000851520). Quantitative cross-checks via SEC EDGAR XBRL and public market-data aggregators (unofficial, reconciled to filings). Legal/industry: Federal Rule of Evidence 702 (amended 2023-12-01); CPSC recall data.

No BUY/SELL recommendation or price target appears anywhere in the numbered analysis above; the single position taken in this document is the clearly-labeled Claude’s Take block at the top, which is the author’s own view.

Appendix A — Diligence Questionnaire

Exponent, Inc. (NASDAQ: EXPO) · 2026-06-04 Supplemental to the main note. Fact/Interpretation/Assumption labels applied where material. No BUY/SELL, no price target.

General

What thoughtful questions have other investors asked about this company? The recurring questions are all about price and growth, not quality: (1) Is the slowdown cyclical or structural? — the evidence says cyclical (a self-inflicted utilization trough + soft proactive R&D demand), with Q3’25/Q1’26 reaccelerating. (2) Is ~73% utilization a permanent ceiling? — the single biggest growth-cap unknown. (3) Does ~22x forward still embed too much premium? — a ~70% EV/EBITDA premium to CRAI for a mid-single-digit grower. (4) Why did net income fall in FY2025 if the business is fine? — it didn’t, operationally: pre-tax was flat; the dip was a tax-line SBC swing + biennial costs. (5) Does AI threaten expert-witness work? — consensus: augments, doesn’t replace (Daubert requires human experts). (6) Is the dividend/buyback sustainable? — yes; net cash, FCF > NI, 13-year streak.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Closer to a cyclical low/normalizing — FY2025 ran at a 73% utilization (below the firm’s mid-70s potential) with the proactive book in a tech/auto R&D air-pocket; Q1’26’s 76% utilization suggests the cycle is turning up, not peaking.

Internal actions or external environment? Both, but more controllable than most. Utilization (internal hiring/right-sizing) drove the recent swing; end-market R&D budgets (external) drove the proactive softness. The counter-cyclical reactive core dampens external dependence.

How stable are revenues? More stable than most industrials — reactive work (failures, recalls, litigation) is non-discretionary and counter-cyclical; the business has no commodity exposure and recurring (if not contractual) demand. Quarterly results can be lumpy on large-matter timing.

Outlook / market size? Served markets — litigation/expert-witness, forensic engineering, product safety, EHS/regulatory — are large, fragmented, and growing with product complexity, recall volumes (CPSC +40% 2020→2024), and regulation. EXPO’s growth is talent-gated, not demand-gated.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More at the single-discipline level (EXPO’s 10-K: “barriers to entry are low… competition is increasing”), but EXPO’s integrated, court-credible niche remains defensible.

How profitable (ROIC/ROE)? ~28% ROE; ROIC effectively infinite (net cash, asset-light, minimal capital to grow). ~22–23% operating margin on net revenue.

How profitable is the industry — competitors, barriers? The broad industry is mediocre (fragmented, ~12,000 US expert firms, low single-discipline barriers). EXPO’s niche is highly profitable because the barrier is the bundle: 55-year brand + 90+ disciplines + conflict-clean independence + Daubert track record.

Can the business be easily understood? Yes — it sells expert hours; profitability = utilization × billing rate × FTE, with a 33%-of-pretax bonus pool flexing comp.

Undermined by foreign low-cost labor? No — the work requires US-credentialed, court-admissible experts; it is the opposite of a labor-arbitrage business.

Do brands matter? Decisively yes — “the Exponent name on a report” is the moat. This is the rare consulting firm where brand is the core asset.

Nature of competition / switching costs / barriers to entry? Competition is on credibility and track record. Switching costs are real in litigation (you hire the firm whose experts win; an unproven expert is case risk). The barrier is the integrated brand, not any one discipline. The genuine vulnerability is talent (the PhD bench) and reputation, not competitive entry.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The brand/reputation and the assembled PhD workforce — the core economic assets — are not capitalized (intangible, internally built). Tangible book understates intrinsic value.

Off-balance-sheet liabilities? Minimal — operating-lease liabilities (~$83M, on balance sheet under ASC 842) and a deferred-comp liability offset by rabbi-trust assets. Watch item: the contractual Arizona land-lease step-up (~$1.0M → ~$6.2M/yr from Jan 2028).

How conservative is the accounting? Very — RSUs expensed, leases on balance sheet, services billed as performed (no aggressive pull-forward), no acquisition/goodwill churn (goodwill flat $8.6M), no impairments, KPMG auditor since 1987 with a clean opinion. Earnings quality is high (FCF > NI).

How CapEx-hungry? Barely — capex 1.6–3.0% of net revenue. Asset-light; the firm grows by hiring, not by building.

Capital Allocation & Management

How much FCF, and how is it used? ~$122M FCF (FY2025); returned via a growing dividend ($1.20/sh, 13-yr streak) and buybacks ($97.8M FY25). FY2025 returned ~$158.6M — more than it earned — drawing down cash. Philosophy: return the excess; no debt, no M&A.

Recent significant acquisitions? None — EXPO is a pure organic grower (a positive: no integration risk, no value-destroying deals).

Buying back shares? Yes, opportunistically — stepped up 17-fold to $97.8M in FY2025 (~$72/sh) into the share weakness; net diluted share count fell. New $100M (Oct’25) + $50M (Apr’26) authorizations.

Issuing large amounts of new shares to insiders? SBC ~4.4% of net revenue — meaningful but disclosed, tied to the bonus-pool/RSU structure, and now over-offset by buybacks. Net dilution is negative (count shrinking).

Director/management compensation? Bonus pool = 33% of pre-bonus pretax profit (aligns workforce with profitability). CEO total comp ~$3.74M (modest; ~19:1 pay ratio). Say-on-pay 95.7%. Gap: CEO performance metrics (+3% revenue, margin target) are undemanding and lack a per-share/ROIC/TSR linkage.

Motivations of management? A profit-sharing culture aligned with margins and retention; modest CEO pay; disciplined capital return. The missing piece is an explicit per-share/return-on-capital incentive.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a standard US C-corp common stock (1099, not K-1).

Dividend policy? Growing dividend, ~$1.20/sh, ~8% CAGR, 13 consecutive years, ~55–57% payout, ~2.1% yield — well-covered by FCF.

How profitable is the business? Among the most profitable in public markets for its size — ~28% ROE, ~22–23% operating margin on net revenue, net cash.

Net income diverging from cash from operations? Favorably — FCF runs 110–126% of net income (SBC + D&A add-backs exceed low capex). The FY2025 CFO dip was a receivables build funding higher revenue, not an earnings-quality issue.

Risks & Downside

What would cause the stock to decline? A continued multiple de-rate if the cyclical recovery stalls (utilization stuck at ~73%, rate-only growth); persistent tech/auto R&D weakness; a reputation-damaging engagement; or simply a re-rating toward the high-teens where slower consulting peers trade.

Risk of catastrophic loss? Very low — net cash, no debt, asset-light, diversified client base. Financial-distress/solvency risk is negligible. The risk is valuation and growth, not survival.

Chance of total loss? Negligible absent a catastrophic, sustained reputation collapse that destroyed the brand — the only asset whose loss would be existential, and there is no evidence of erosion.

Recent News & Events

Has the business environment changed recently? Modestly: (1) a cyclical demand recovery is underway (Q3’25, Q1’26 both +10% revenue; utilization to a cycle-high 76%); (2) an orderly leadership transition (new CFO Anderson and President Pye eff. May 1, 2026; Chairman Richardson eff. today’s June 4 annual meeting, succeeding the retiring Johnston; Corrigan continues as CEO); (3) soft big-tech/auto R&D budgets and chemical-regulatory activity (the FY2025 soft spots) showing early recovery in the proactive book.

Significant acquisitions? None (organic-only).

Recent change in accounting policies? None material. Note the 53-week FY2024 calendar quirk distorts year-over-year growth optics — use net-revenue, week-adjusted comps.

Recent changes — new markets, facilities, management? New CFO/President/Chairman (internal-continuity); the Arizona land-lease extension (occupancy expansion, with the 2028 rent step-up). Recent news flow has been quiet — only a routine 10b5-1 insider sale, non-thesis-changing.

Frameworks applied: Greenwald — the moat is an intangible asset (court/Daubert-tested brand) reinforced by economies of scale within a niche (90+ disciplines, conflict-clean independence); validated by pricing power and ~28% ROE — a genuine, durable advantage, the opposite of the no-moat commodity profile. Marathon capital-cycle — not a capital-intensive supply-cycle business; the relevant “cycle” is the internal utilization/hiring cycle (over-hire → right-size → re-accelerate) plus client R&D budgets, both of which the data shows turning up. Where the generic metric doesn’t fit (e.g., conventional ROIC on a net-cash firm), the sector-appropriate analog is given (return on a near-zero capital base / FCF conversion).

Appendix B — Source Appendix

Exponent, Inc. (NASDAQ: EXPO) — Science & Engineering Consulting As of: 2026-06-04 SEC CIK: 0000851520

Sources are grouped Primary → Secondary. Primary sources (SEC filings, company disclosures) take precedence; every material number in the note reconciles to a primary filing.

A. PRIMARY SOURCES — SEC FILINGS (trailing 36 months)

Annual Reports (Form 10-K)

Quarterly Reports (Form 10-Q)

Current Reports (Form 8-K) — material events

Proxy Statements (DEF 14A)

Insider Transactions (Forms 4 / 5 / 3)

• 139 Form 4 + 8 Form 5 + 3 Form 3 over the 36-month window, parsed from raw EDGAR XML. Transaction-code tally: M=156, S=67, A=56, F=25, G=5, P=0 — zero open-market purchases; all selling is Rule 10b5-1-planned cashless-exercise / diversification.
• Representative item: James Bradley A (Group VP) open-market sale 2,000 sh @ $57.47, 2026-05-27 — https://www.sec.gov/Archives/edgar/data/851520/000085152026000076/ (10b5-1, routine).

SEC EDGAR (authoritative XBRL / index)

• Company filing index: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000851520&type=10-K

B. PRIMARY SOURCES — REGULATORY / LEGAL FRAMEWORK

C. SECONDARY SOURCES — MARKET DATA

D. SECONDARY SOURCES — INDUSTRY / MARKET SIZING

TAM caveat: third-party market-sizing in this space varies up to ~10x by source; all figures are ORDER-OF-MAGNITUDE. EXPO’s true addressable market is best triangulated from its own segment/end-market disclosure.

E. SECONDARY SOURCES — NEWS / COMMENTARY / COMPETITIVE